AUS
NZ
UK
CA
USA
IND
Highlights
- CSL Ltd continues to show steady revenue growth with rising profits.
- The company's debt/equity ratio indicates a strong capital structure.
- CSL reported a 14.6% return on equity, signaling efficient capital usage.
CSL Ltd (ASX:CSL) has seen its stock rise by 1.93% in 2024, gaining attention from market watchers. This biotechnology company operates globally, delivering innovative healthcare solutions that save lives and improve public health. CSL’s operations are structured into three main divisions: CSL Behring, CSL Seqirus, and CSL Vifor, offering a broad range of products and services. CSL Behring, focused on plasma therapies, and CSL Seqirus, known for flu vaccines, are major drivers of growth. CSL Vifor specializes in treatments for iron deficiency and kidney care, establishing TSX:CSL as a key player in the ASX healthcare stock sector.
In the last financial year, CSL reported annual revenue of $14.8 billion, showing a compound annual growth rate (CAGR) of 12.8% over the past three years. This highlights the company’s ability to generate increasing revenue over time. A gross margin of 52.1% reflects strong profitability from core products and services before accounting for overheads, while its profit for the last financial year was $2.6 billion, up from $2.3 billion three years ago, with a CAGR of 3.6%.
When assessing CSL's financial health, it’s essential to consider its capital structure. The company holds net debt of $10.5 billion, reflecting its borrowing minus available cash. Though a high number, CSL maintains a debt/equity ratio of 62.8%, suggesting a balanced approach between debt and equity. This ratio indicates that the company is leveraging its equity effectively without relying excessively on borrowing.
CSL’s return on equity (ROE) is another important metric. For the fiscal year 2024, CSL posted an ROE of 14.6%, demonstrating that the company is effectively using shareholder equity to generate profit. This figure implies that the company allocates its capital well, ensuring that profits are being maximized relative to its equity.
With steady growth in revenue, profitability, and a solid ROE, CSL remains an important company to watch in the healthcare and biotechnology sectors. However, further analysis of its financials and comparison with peers is crucial to gain a complete understanding of its performance.
